ODM 104

Drug Profile

ODM 104

Alternative Names: ODM-104

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Germany (PO, Capsule)
  • 03 Aug 2017 Orion completes a phase I pharmacokinetics trial in Parkinson disease (In volunteers) in Finland (NCT03140956)
  • 09 Jun 2017 Orion completes the COMDOS1, dose-finding phase I pharmacokinetics trial in Healthy volunteers in Germany (NCT03055936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top